Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral NDec in Sickle Cell Disease
2023-508506-22-00Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of decitabine + tetrahydrouridine in sickle cell disease (SCD) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in total haemoglobin. Started Jun 2024; status: completed.
02
Drugs
decitabine + tetrahydrouridine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2023-508506-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508506-22-00.